Franklin Resources
MLYS icon

Franklin Resources’s Mineralys Therapeutics MLYS Stock Holding History

Franklin Resources’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.1M Sell
1,635,520
-149,142
-8% -$4.09M 0.01% 719
2026
Q1 		$48.3M Sell
1,784,662
-4,085
-0.2% -$120K 0.01% 659
2025
Q4 		$64.9M Sell
1,788,747
-21,021
-1% -$843K 0.02% 555
2025
Q3 		$68.6M Buy
1,809,768
+6,171
+0.3% +$133K 0.02% 538
2025
Q2 		$24.4M Buy
1,803,597
+23,556
+1% +$341K 0.01% 870
2025
Q1 		$28.3M Buy
1,780,041
+34,444
+2% +$396K 0.01% 798
2024
Q4 		$21.5M Buy
1,745,597
+84
+0% +$1.1K 0.01% 890
2024
Q3 		$23.7M Buy
1,745,513
+262,922
+18% +$3.18M 0.01% 841
2024
Q2 		$17.3M Buy
1,482,591
+575,080
+63% +$7.24M 0.01% 904
2024
Q1 		$11.7M Buy
907,511
+208,044
+30% +$2.57M ﹤0.01% 1023
2023
Q4 		$6.02M Buy
699,467
+249,450
+55% +$1.96M ﹤0.01% 1067
2023
Q3 		$4.28M Buy
450,017
+17
+0% +$222 ﹤0.01% 1135
2023
Q2 		$7.67M Hold
450,000
– – ﹤0.01% 986
2023
Q1 		$7.05M Buy
+450,000
New +$7.58M ﹤0.01% 1011

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources's MLYS Position: Q2 2026 in Review

Franklin Resources reduced its Mineralys Therapeutics (MLYS) stake by 8.4% in Q2 2026, selling an estimated $4.09M and leaving 1,635,520 shares worth $44.1M. The position accounts for 0.01% of the portfolio, ranked #719.

Franklin Resources first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $68.6M in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Franklin Resources held 1,635,520 shares of Mineralys Therapeutics worth $44.1M as of Q2 2026.
  • Franklin Resources sold 149,142 Mineralys Therapeutics shares in Q2 2026, an estimated $4.09M.
  • Mineralys Therapeutics made up 0.01% of Franklin Resources's portfolio in Q2 2026, its #719 holding.
  • Franklin Resources first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Franklin Resources's Mineralys Therapeutics position peaked at $68.6M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.